FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • FAQ
  • How to use FRC

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Commodities

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Decision Diagnostics Corp. Stock AnalysisComprehensive stock analysis for Decision Diagnostics Corp. (DECN) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisDECN
DECN
Decision Diagnostics Corp.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
DECN
Home🔹Stocks🔹Decision Diagnostics Corp.

Decision Diagnostics Corp.

🇺🇸DECN•OTC

Decision Diagnostics Corp.

🇺🇸DECN•OTC
Market cap
$35.45K
Sentiment

Your view on DECN

Mkt Cap
$35.45K
Sentiment
Your view
DECN
Decision Diagnostics Corp.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
DECN
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Decision Diagnostics Corp.

Industry
Medical - Pharmaceuticals
Sector
Healthcare
CEO
Keith Berman
Headquarters
2660 Townsgate Road, Westlake Village, CA, US
Industry
Medical - Pharmaceuticals
Sector
Healthcare
CEO
Keith Berman
Headquarters
2660 Townsgate Road, Westlake Village, CA, US
Description

Decision Diagnostics Corp. develops smart phone based electronic medical record (EMR) technologies.

The company offers prescription and non-prescription diagnostics; home testing products for the chronically ill; fulfillment services to direct to patient diabetes programs; and cell phone centric e-health products and technologies development services. It manufactures and distributes GenUltimate!

glucose test strips, a Class II medical device for at-home use for the measurement of glucose; PetSure! glucose test strip for the glucose testing of dogs and cats designed to work with the Zoetis AlphaTrak and AlphaTrak II glucometers, a legacy meter; GenUltimate!

4Pets Glucose system, a proprietary glucose measuring system, including GenUltimate! 4Pets test strip and Avantage meter, for the testing of dogs, cats, and horses; and GenUltimate! Sure and GenUltimate! Precis test strips.

In addition, it engages in the acquisition and holding of intellectual property including patents and trademarks and specialty manufacturing equipment.

Further, the company also provides MD@Hand, an inpatient/outpatient management suite; Practice Probe, a data mining utility used to extract information from the physician's practice management system; and ResidenceWare, a residential management system that facilitates the relay of information from commercial and residential real estate management companies to occupying tenants using networking software systems and applications.

Its EMR technologies are used by physicians at the point of care. The company was formerly known as InstaCare Corp. and changed its name to Decision Diagnostics Corp. in November 2011. Decision Diagnostics Corp. was founded in 2000 and is based in Westlake Village, California.

FRC Research

Media

Infographics, videos, and posts covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks it is worth vs. the current price.

FRC's fair value estimate for Decision Diagnostics Corp., and the rating behind it. DECN last traded at $0.0001; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Valuation, profitability, liquidity and leverage ratios for Decision Diagnostics Corp.. Starting points for Decision Diagnostics Corp.: EPS -$0.11, beta -0.10 — an Medical - Pharmaceuticals name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Dividend history, yield and payout sustainability for Decision Diagnostics Corp.. Decision Diagnostics Corp. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Reported vs. expected earnings history for Decision Diagnostics Corp.. Trailing twelve-month EPS for Decision Diagnostics Corp. stands at -$0.11. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Income statement, balance sheet and cash flow history for Decision Diagnostics Corp.. Decision Diagnostics Corp. has reported as a listed company since 2002. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Decision Diagnostics Corp. valued side by side against its closest peers. Decision Diagnostics Corp. is measured against Medical - Pharmaceuticals peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.

Ownership & News

Institutional Ownership

Premium

Which funds and firms own the stock.

Which institutions hold Decision Diagnostics Corp., and how their positions are changing. At a $35,450 market value, institutional positions materially move Decision Diagnostics Corp.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.

Insider Trading

Premium

Recent buying and selling by company executives.

Buying and selling by Decision Diagnostics Corp. executives and directors. Shares of Decision Diagnostics Corp. have traded between $0.0001 and $0.0001 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.

Senate Trading

Premium

U.S. Senator disclosures filed under the STOCK Act.

U.S. Senate disclosures naming Decision Diagnostics Corp.. Decision Diagnostics Corp. is a $35,450 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.

House Trading

Premium

U.S. Representative disclosures filed under the STOCK Act.

U.S. House of Representatives disclosures naming Decision Diagnostics Corp.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.

News

Latest headlines and market coverage.

Latest headlines and company announcements for Decision Diagnostics Corp.. Coverage tracks Decision Diagnostics Corp. within Medical - Pharmaceuticals (Healthcare). Press releases and market coverage, newest first.

Peer companies

  • AMBS — Amarantus BioScience Holdings, Inc.
  • IBXG — iBX Group, Inc.
  • ITMC — Itoco Inc.
  • LGND — Ligand Pharmaceuticals Incorporated
  • PRMD — Primemd Inc.
  • RGDXQ — Response Genetics, Inc
  • ROTH — PharmaRoth Labs, Inc.

More Medical - Pharmaceuticals companies

  • PNPL — Pineapple, Inc.
  • POM — POMDOCTOR Ltd
  • PRPH — ProPhase Labs, Inc.
  • PXYN — Praxsyn Corporation
  • QMDT — Quick-Med Technologies, Inc.
  • RADLY — Raia Drogasil S.A.
  • RBII — Rising BioSciences, Inc.
  • RCDTF — Recordati Industria Chimica e Farmaceutica S.p.A.
  • RGEDF — Gedeon Richter PLC
  • RLLVF — Relevium Technologies Inc.
  • RMRK — Rimrock Gold Corp.

News

Latest Market News